Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Pfizer And Biontech Seek Covid Vaccine Emergency Approval

By Gorilla Trades. Originally published at ValueWalk.

Pfizer Biontech AstraZeneca Covid Vaccine Results moderna covid-19 vaccine

Commenting on Pfizer and Biontech filing for the emergency approval of their coronavirus vaccine candidate in Europe and today’s trading, Gorilla Trades strategist Ken Berman said:


Q3 2020 hedge fund letters, conferences and more

Pfizer And Biontech File For Emergency Approval

The major indices are all trading significantly higher at midday, erasing yesterday’s losses and closing in on their record highs. The Nasdaq and the S&P 500 already hit new all-time highs in early trading, and the Dow also recaptured the historic 30,000 level. Risk assets surged higher overnight, lifting U.S. index futures following yesterday’s month-end profit-taking dip on Wall Street. Pfizer (PFE, +3.5%) and Biontech (BNTX, -3.7%) filed for the emergency approval of their COVID vaccine candidate in Europe as the push for the global distribution of the vaccines is gaining steam, supporting risk assets across the board.

In economic news, the ISM manufacturing PMI was a tad below the consensus estimates, but it remained firmly above the key 50 level, and since construction spending beat expectations, the outlook for the sector remains bright. Even though the Eurozone Consumer Price Index missed expectations and nearly all of the European manufacturing PMIs have been revised lower, the global rally remained intact. Stocks added to their early gains after a bipartisan group of senators released a $900 billion stimulus proposal in an attempt to restart the negotiations between the two parties and provide quick relief amid the resurgence of the virus.

Market Wrap

Dow: 29,946, + 308 or 1.0%

S&P 500: 3,669 + 47 or 1.3%

Nasdaq: 12,340, + 142 or 1.2%

Russell 2000: 1,840, + 20 or 1.1%




Market breadth has been relatively strong this morning, with advancing issues outnumbering decliners by a more than 5-to-1 ratio on the NYSE at midday
. Only 2 stocks hit new 52-week lows on the NYSE and the Nasdaq, while 164 stocks hit new 52-week highs. The major indices have been trading above their daily VWAPs (Volume-Weighted Average Price) for most of the morning session, pointing to intraday buying pressure. Yesterday’s trends reversed this morning, yet again, at the level of the main sectors, as the positive vaccine-related developments triggered a strong rebound in the hardest-hit industries and cyclical issues, while the key defensive sectors and tech stocks have been showing relative weakness in the first hours of trading. Stay tuned!

The post Pfizer And Biontech Seek Covid Vaccine Emergency Approval appeared first on ValueWalk.

Sign up for ValueWalk’s free newsletter here.


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!